GCCA
30.3.2022 08:02:04 CEST | Business Wire | Press release
The Global Cement and Concrete Association (GCCA) has today launched a series of Net Zero Accelerator initiatives to help national cement and concrete industries decarbonise in line with the GCCA’s 2050 Net Zero Global Industry Roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005500/en/
The first wave of Accelerators will launch in Egypt, which later this year will be the host country for COP27, as well as in India, Thailand and Colombia. These countries combined represent approximately 10% of global cement and concrete production. Concrete, a local and durable material, is fundamental to overcoming sustainable development challenges which many parts of the world are facing, such as population growth, increasing urbanisation and the need for more resilient infrastructure and communities in the face of a rapidly changing climate.
Globally, cement and concrete manufacture accounts for around 7% of CO2 emissions. The global plan to eliminate these emissions by 2050 requires all parts of the world to accelerate the reductions in CO2 emissions. The Accelerator program will identify the barriers to decarbonisation in target countries and recommend key actions. This includes encouraging government policies that can have an immediate impact, such as better recycling, the use of waste as an alternative to fossil fuels, and other circular economy practices. It will also include identifying lighthouse projects that can fully eliminate emissions over the next decades, such as carbon capture utilisation and storage technologies.
Thomas Guillot, GCCA Chief Executive, said: “Last year our industry made a breakthrough net zero global commitment. This is the next logical step as we move our focus from a global roadmap to driving decisive local action.
“Concrete will continue to be the world’s most used building material for decades to come, meaning global cooperation between governments and industry is crucial to ensuring net zero targets are met. Our Net Zero Accelerators will offer collaboration and support to a number of target countries to help them decarbonise and align with the global roadmap. I’m proud to launch the first phase of the Accelerator program to assist these nations in embracing greener technologies and work towards a more sustainable future together. I now call on more partners around the world to join us and be part of this movement.”
His Excellency, Dr Mahmoud Mohieldin, COP 27 UNFCCC High-Level Champion of Egypt, said: “Much of the infrastructure the world needs to overcome our major global challenges – such as alleviating poverty, the need for clean water and energy, and safe, affordable housing – is yet to be built.
“Cement and concrete will play a critical role in delivering a healthier, more resilient, zero carbon world as the industry moves to rapidly and fully decarbonise. As such, we are pleased to support the Net Zero Accelerator initiative, helping developing countries achieve their decarbonisation targets, as we work to support all industries and countries with their climate ambitions to help build a more sustainable future for all. The full and willing participation of a sector which accounts for 7-8% of global CO2 emissions is critical to contribute to the goal of the 2015 Paris Climate Change Agreement to limit global warming well below 2°C degrees and as close as possible to 1.5°C.”
The accelerator programme comprises three elements – i. net zero national roadmaps including emissions forecasts, reduction levers, policy needs and the industry commitment; ii. identification and funding exploration for large scale carbon cutting ‘Lighthouse’ Projects; and iii. policy dialogues with national governments to help accelerate the transition.
The GCCA is partnering with the cement and concrete industry on the ground and will work closely with policymakers, designers, and the construction sector to help overcome procurement and resourcing challenges, as well as demonstrate the business case for greener technologies to be used on a wider scale.
The Accelerators will help align Phase 1 countries’ cement and concrete industries with the GCCA’s 2050 Net Zero Roadmap , which marked the biggest global commitment by a heavy industry to decarbonise when it was launched last year. The Roadmap sets out a path to fully decarbonise by 2050, a target aligned with the Paris Agreement to limit global warming to 1.5°C. The roadmap actions between now and 2030, to reduce concrete related emissions by 25%, will prevent almost 5 billion tonnes of carbon from entering the atmosphere compared to a business-as-usual scenario.
Lighthouse Projects and a new tranche of phase two Accelerators will be announced later this year.
-ends-
Notes to editors:
About the GCCA:
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. In this way, the association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. The GCCA is headquartered in London, England. It complements and supports the work done by associations at the national and regional levels.
The GCCA works with key a range of partners. It co-leads the Mission Possible Partnership’s Concrete Action for Climate initiate with the World Economic Forum. The GCCA is also an official accelerator for the Race to Zero.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
